LBF18107PG01: Difference between revisions

Revision as of 04:03, 21 April 2010

Upper classes: LB LBF

2,3-Dinor-6-keto Prostaglandin F_1α

Structural Information
	5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid
	2,3-Dinor-6-keto Prostaglandin F_1α
	2,3-DINOR-6-KETO-PGF1 alpha
Formula	C18H30O6
Exact Mass	342.204238692
Average Mass	342.42719999999997
SMILES	`[C@@H]([C@@H](CC(=O)CCC(O)=O)1)(C=C[C@H](O)CCCCC)[C@H](O)C[C@@H]1O`
Physicochemical Information



	[ α ]20.2 D = +16.9° (C=1.76 CHLOROFORM, measured after 24 hours at 20°C)

	METHANOL Pace-Asciak_CR et al.
	When prostaglandin I2 or its non-enzymatic degradation product (6-keto-prostaglandin F1 alpha ) was infused into man, a major urinary metbolite was 2,3-dinor-6-keto-prostaglandin F1 alpha , a beta -oxidation product Needleman_P et al..





Spectral Information
Mass Spectra	METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M⁺), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 Pace-Asciak_CR et al.
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms

Reported Metabolites, References

Biospecies	ID	Compound Name	Reference	Comment
n.a.	LBF18107PG01	See above.	Needleman_P et al. 1986
n.a.	LBF18107PG01	See above.	Pace-Asciak_CR et al. 1977

@@ Line 7: / Line 7: @@
 |LipidMaps=LMFA03010089
 |SysName=5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid
-|Common Name=&&2,3-Dinor-6-ketoprostaglandin F_1alpha&&
+|Common Name=&&2,3-Dinor-6-keto Prostaglandin F_1alpha&&
 |Optical=[ alpha ]^{20.2}_D = +16.9° (C=1.76 CHLOROFORM, measured after 24 hours at 20°C) <!--1060-->
 |Solubility=METHANOL [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]]